Steven P. Coen - 21 Aug 2026 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Reporting relationship: Chief Financial Officer
Issuer ticker: DNA
Reported as of: 21 Aug 2026
Net transaction value: -$2,302
SEC form: 4
Accepted by SEC: 25 Aug 2026, 17:01:16 UTC
Prior SEC filing: 20 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Karen Tepichin, Attorney-in-Fact

Key filing fact

Steven P. Coen filed Form 4 for Ginkgo Bioworks Holdings, Inc. (DNA) on 25 Aug 2026.

Key facts

This page summarizes Steven P. Coen's Form 4 filing for Ginkgo Bioworks Holdings, Inc. (DNA).
5 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 25 Aug 2026, 17:01.

Change

Previous filing in this sequence was filed on 20 Jul 2026.
Current net transaction value: -$2,302.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001977441 Primary reporting owner

Coen Steven P.

Relationship: Chief Financial Officer
Address: C/O GINKGO BIOWORKS HOLDINGS, INC., 27 DRYDOCK AVENUE, BOSTON
Signature: /s/ Karen Tepichin, Attorney-in-Fact
Signature date: 25 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DNA transaction

Class A Common Stock

Options Exercise

Transaction value
Shares: +587
Change %: +1.1%
Price
Shares after: 52,025
Date: 21 Aug 2026
Ownership: Direct
Footnotes: F1

DNA transaction

Class A Common Stock

Options Exercise

Transaction value
Shares: +156
Change %: +0.3%
Price
Shares after: 52,181
Date: 21 Aug 2026
Ownership: Direct
Footnotes: F1

DNA transaction

Class A Common Stock

Sale

Transaction value: $2,302
Shares: -330
Change %: -0.63%
Price: $6.98
Shares after: 51,851
Date: 24 Aug 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DNA transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -587
Change %: -10%
Price
Shares after: 5,296
Date: 21 Aug 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 587
Exercise price
Footnotes: F1, F3

DNA transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -156
Change %: -5%
Price
Shares after: 2,975
Date: 21 Aug 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 156
Exercise price
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Footnote F2

Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock and/or restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.

Footnote F3

The RSUs vest as follows: 25% of the underlying shares vested on May 1, 2024, then 36 equal monthly installments thereafter.

Footnote F4

The RSUs vest as follows: 2/48ths of the underlying shares vested on May 1, 2024, then 46 equal monthly installments thereafter.

SEC remarks

Chief Financial Officer